Massachusetts experienced a more than 36% decrease in opioid-related overdose deaths in 2024, the state Bureau of Substance Addiction Services reported this week, and local statistics show an even larger drop.
The statewide data shows that opioid-related overdose deaths dropped to the lowest level since 2013 — a decline seen across all races and ethnicities, according to Bureau Director Deirdre Calvert. There were 1,763 opioid-related deaths between July 2023 and June 2024 in Massachusetts.
In Franklin County and the North Quabbin region, the decline in opioid-related overdose deaths was even starker, as the area saw a 62.5% decrease — from 32 deaths in 2023 down to 12 in 2024, according to data from the Opioid Task Force of Franklin County and the North Quabbin Region.
The decrease comes alongside a downward trend in opioid-related overdose deaths across the country. U.S. Centers for Disease Control and Prevention data shows a nearly 27% decrease in drug overdose deaths nationwide from 2023 to 2024. In Boston, data reported in early June showed a 38% decrease in opioid overdose deaths in 2024 compared to 2023, the lowest number since 2015.
Debra McLaughlin, coordinator of the Opioid Task Force of Franklin County and the North Quabbin Region, celebrated the “impressive decline,” but emphasized the enormous human loss Franklin County, Massachusetts and the country have experienced.
“I want to underscore that every number on this graph represents a real person who had a family and their losses can be felt in our rural region for years to come,” McLaughlin said. “No matter how small the numbers ultimately are, it really represents a significant loss in our community that can’t be understated.”
The decrease comes as the drug supply continues to be tainted with often deadly substances like fentanyl, xylazine and other stimulants, Calvert noted. While only about 88.1% of all opioid-related overdose deaths in Massachusetts in that period had a toxicology screen available, screenings found fentanyl present in almost 92% of opioid-related overdose deaths.
“In recent years, fentanyl has been mixed with the veterinary sedative xylazine,” Calvert said. “In 2024, xylazine was found in 34% of samples tested by the Massachusetts drug supply data stream and in 16% of opioid overdose deaths.”
Advocates, people with experience in substance use and state officials point to investments in substance use prevention, treatment, recovery and harm reduction as a major factor in the decline in overdose deaths. The accessibility of the overdose reversal medication naloxone, commonly known by the brand name Narcan, has also grown in recent years, which experts say significantly helps decrease the chances that substance users experience death from opioid overdoses.
McLaughlin highlighted the Opioid Task Force’s efforts to distribute more than 5,000 naloxone kits to first responders and the public since 2021, as well as continued outreach to let folks know about recovery resources and increase education about substance use disorder.
“There’s also increased awareness of substance use disorder as a brain disorder. I think that has helped people make it easier to get the help that they need,” McLaughlin said. “The stigma is alive and well and we still have much more work to do in that space. There continues to be way too much shame for people who struggle with this.”
Calvert said Wednesday that while these efforts are necessary to continue to see deaths decline, the mixture of federal, state and other funding the Bureau of Substance Addiction Services receives isn’t matching demand.
“BSAS serves as the payer of last resort for substance use disorder treatment coverage in the commonwealth, which means we reimburse for services rendered to uninsured and underinsured individuals. There has been a growing demand for BSAS coverage, and while this is an important function of BSAS, it is not fully funded in our appropriations,” Calvert said. Billing to the bureau has outpaced its appropriations, she added.
Given the increases in MassHealth reimbursements and billings to the bureau, its report Wednesday said that potential Medicaid cuts “will likely cause some individuals to lose their insurance coverage and increase the burden on BSAS.”
McLaughlin raised several concerns about impending Medicaid cuts, as the system is the largest payer of substance use treatment services in the United States and rural regions will be “disproportionately impacted.”
“The very concerning cuts to Medicaid that were just passed at the federal level are alarming, particularly the risks to rural regions,” she said. “Any kind of reduction in services can only result in more serious and more dire health outcomes, including addiction, because that support system for millions of Americans is being reduced.”
Chris Larabee can be reached at clarabee@recorder.com. Information from State House News Service was used in this report.